These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25047158)

  • 1. [Homozygous and compound heterozygous RYR1 mutations. New findings on prevalence and penetrance of malignant hyperthermia].
    Wolak S; Rücker B; Kohlschmidt N; Doetsch S; Bartsch O; Zechner U; Tzanova I
    Anaesthesist; 2014 Sep; 63(8-9):643-50. PubMed ID: 25047158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family.
    Rueffert H; Olthoff D; Deutrich C; Thamm B; Froster UG
    Br J Anaesth; 2001 Aug; 87(2):240-5. PubMed ID: 11493496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
    Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
    Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations.
    Ibarra Moreno CA; Hu S; Kraeva N; Schuster F; Johannsen S; Rueffert H; Klingler W; Heytens L; Riazi S
    Anesthesiology; 2019 Nov; 131(5):983-991. PubMed ID: 31206373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
    Klingler W; Heiderich S; Girard T; Gravino E; Heffron JJ; Johannsen S; Jurkat-Rott K; Rüffert H; Schuster F; Snoeck M; Sorrentino V; Tegazzin V; Lehmann-Horn F
    Orphanet J Rare Dis; 2014 Jan; 9():8. PubMed ID: 24433488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.
    Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I
    Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
    Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
    Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
    Heytens L
    Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
    Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.
    Kraeva N; Heytens L; Jungbluth H; Treves S; Voermans N; Kamsteeg E; Ceuterick-de Groote C; Baets J; Riazi S
    Neuromuscul Disord; 2015 Jul; 25(7):567-76. PubMed ID: 25958340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
    Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
    Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
    Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
    Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis.
    Broman M; Heinecke K; Islander G; Schuster F; Glahn K; Bodelsson M; Treves S; Müller C
    Anesth Analg; 2011 Nov; 113(5):1120-8. PubMed ID: 21965348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.